Nicotinamide Encyclopedia — Scientific Background

What Is Nicotinamide?

Nicotinamide (CAS 98-92-0), also known as niacinamide, nicotinic acid amide, or 3-pyridinecarboxamide, is the water-soluble amide form of vitamin B3 with the molecular formula C₆H₆N₂O and a molecular weight of 122.13 g/mol. It is chemically characterized as pyridine-3-carboxamide and occurs as a white crystalline powder or colorless needles with a melting point of 128–131°C. Nicotinamide is odorless or has a slight characteristic odor, has a slightly bitter taste, and is freely soluble in water (1000 g/L) and ethanol. It was first isolated from rice bran in 1911 and is one of the two primary forms of vitamin B3, the other being nicotinic acid.

The Two Forms of Vitamin B3: Nicotinamide vs. Nicotinic Acid

Vitamin B3 exists in two primary forms used in supplementation, which differ significantly in their pharmacological profiles:

Nicotinamide (Niacinamide) — This form does not cause flushing and does not significantly affect lipid levels. It is the preferred form for high-dose vitamin B3 supplementation, skin health applications, and cellular energy support. Nicotinamide is the form used in the ONTRAC skin cancer prevention trial and is widely used in dermatological and cosmeceutical applications.

Nicotinic Acid (Niacin) — This form causes the characteristic flushing reaction and significantly affects cholesterol levels, lowering LDL and triglycerides while raising HDL. High-dose nicotinic acid is FDA-approved as a prescription drug (Niaspan) for lipid disorders, but its use is limited by flushing and potential hepatotoxicity.

Both forms are converted into NAD+ in the body, and biological responses are virtually equivalent when taken in common doses. However, only nicotinic acid has the lipid-regulating effects that make it valuable for cardiovascular applications, while nicotinamide is preferred for skin health and high-dose cellular support.

Physiological Functions of Nicotinamide

Nicotinamide is a critical nutrient with several essential physiological roles:

• NAD+ and NADP+ Cofactor Synthesis — Nicotinamide is a direct precursor to nicotinamide adenine dinucleotide (NAD+) and its phosphate form (NADP+), which are essential coenzymes in cellular Energy Metabolism, redox homeostasis, and DNA repair. Over 400 enzymes require NAD+ to catalyze reactions within the body, including those involved in glycolysis, the Krebs cycle, and the electron transport chain.

• Cellular Energy Metabolism — NAD+ is indispensable for ATP production through oxidative phosphorylation. Nicotinamide supports mitochondrial function and cellular energy metabolism, particularly in tissues with high energy demands such as the brain, heart, and skeletal muscle.

• DNA Repair — NAD+ is the substrate for poly-ADP-ribose polymerase (PARP), an enzyme that catalyzes the transfer of ADP-ribose units from NAD+ to acceptor proteins at sites of DNA damage. This PARP-mediated DNA repair mechanism is essential for genomic stability and cancer prevention.

• Skin Health — Nicotinamide improves skin barrier function by stimulating ceramide synthesis and enhancing the production of skin barrier lipids. It reduces hyperpigmentation by inhibiting melanosome transfer from melanocytes to keratinocytes, and reduces photoaging by preventing UV-induced immunosuppression and enhancing DNA repair.

• Neuroprotection — Nicotinamide has demonstrated neuroprotective effects in preclinical models, including protection against ischemic brain injury and neurodegenerative conditions. It supports neuronal survival through NAD+-dependent mechanisms and modulation of oxidative stress.

• Immune Function — Nicotinamide modulates immune function and has anti-inflammatory properties. It inhibits neutrophil chemotaxis and reduces pro-inflammatory cytokine production.

Mechanisms of Action

NAD+ Biosynthesis and Cellular Energy Metabolism

Nicotinamide is converted to NAD+ through the NAD+ salvage pathway. Nicotinamide is first converted to nicotinamide mononucleotide (NMN) by nicotinamide phosphoribosyltransferase (NAMPT), and NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT). This pathway is highly efficient and is the primary mechanism by which oral nicotinamide raises systemic NAD+ levels. NAD+ functions in intracellular respiration as a codehydrogenase with enzymes involved in the oxidation of fuel molecules such as glyceraldehyde 3-phosphate, lactate, alcohol, 3-hydroxybutyrate, pyruvate, and α-ketoglutarate.

DNA Repair — PARP-Mediated Mechanism

NAD+ is the substrate for poly-ADP-ribose polymerase (PARP), an enzyme found in the nuclei of eukaryotic cells that catalyzes the transfer of many ADP-ribose units from NAD+ to an acceptor protein and also to the enzyme itself. These nuclear poly-ADP-ribose proteins function in DNA replication and repair. Nicotinamide supplementation supports PARP-mediated DNA repair, contributing to genomic stability and reduced cancer risk. This mechanism underlies the clinically validated reduction in non-melanoma skin cancers observed in the ONTRAC trial.

Skin Barrier and Pigmentation — Ceramide Synthesis and Melanosome Transfer Inhibition

Nicotinamide improves skin barrier function by stimulating ceramide synthesis and enhancing the production of skin barrier lipids. It also reduces hyperpigmentation by inhibiting melanosome transfer from melanocytes to keratinocytes without affecting melanin synthesis. Additionally, nicotinamide prevents UV-induced immunosuppression and enhances DNA repair, reducing the risk of skin cancer and photoaging. liposomal formulations enhance these effects by enabling deeper penetration into the stratum corneum and improving skin barrier reinforcement.

Anti-Inflammatory Activity — Neutrophil Chemotaxis Inhibition

Nicotinamide exhibits anti-inflammatory activity through inhibition of neutrophil chemotaxis, modulation of pro-inflammatory cytokine production, and inhibition of poly(ADP-ribose) polymerase overactivation. These mechanisms contribute to its therapeutic potential for inflammatory skin conditions including acne, rosacea, and atopic dermatitis.

The Bioavailability Challenge

Despite its essential physiological functions, native nicotinamide presents significant formulation challenges. The compound is highly water-soluble (1000 g/L), which limits its passive diffusion across biological membranes and its penetration through the stratum corneum of the skin. Following oral administration, nicotinamide is rapidly absorbed and distributed throughout the body, but its hydrophilic nature causes rapid clearance and limited cellular retention. For topical applications, the water-soluble nature of nicotinamide limits its skin penetration, necessitating high concentrations or penetration enhancers to achieve therapeutic efficacy.

These limitations have driven the development of advanced delivery systems, including liposomal encapsulation. Liposomal encapsulation of nicotinamide achieves 80% ± 5% encapsulation efficiency, with stability studies over three weeks at 4°C showing minimal changes in liposomal characteristics. Liposomal formulations significantly improve skin permeation and accumulation of nicotinamide, with enhanced penetration into the stratum corneum and deeper skin layers.

Liposomal Nicotinamide

Liposomal encapsulation of nicotinamide provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the nicotinamide molecule, forming a protective shell that enhances stability, skin permeation, and cellular uptake. This delivery system:

• Achieves 80% ± 5% encapsulation efficiency with good stability over three weeks at 4°C

• Significantly improves skin permeation and accumulation of nicotinamide in the skin

• Enables ceramide and niacinamide to penetrate deeper into the stratum corneum layer, resulting in enhanced skin barrier reinforcement and improved skin lightening effects

• Provides spatial isolation and controlled release, retaining over 85% of each active ingredient during storage

Liposomal encapsulation represents a promising strategy for enhancing the bioavailability and therapeutic efficacy of nicotinamide, particularly for skin health applications where penetration through the stratum corneum is a critical barrier.

Clinical Evidence

Skin Cancer Prevention — ONTRAC Trial

A randomized controlled trial (ONTRAC) of 386 adults with a history of skin cancer found that 500 mg of nicotinamide twice daily (1,000 mg/day) significantly reduced the rate of new non-melanoma skin cancers by 23% (p=0.02) after 12 months. This effect is attributed to NAD+‘s role in DNA repair and cellular energy metabolism. The study demonstrated that nicotinamide provides a safe and effective approach to reducing skin cancer risk in high-risk populations.

Skin Barrier and Pigmentation

Clinical studies have demonstrated that nicotinamide improves skin barrier function, reduces hyperpigmentation, and supports skin lightening. Nicotinamide reduces melanosome transfer from melanocytes to keratinocytes and enhances skin barrier integrity through stimulation of ceramide synthesis. Liposomal formulations enhance these effects by enabling deeper penetration into the stratum corneum and improving skin barrier reinforcement.

Anti-Inflammatory Skin Conditions

Nicotinamide has demonstrated anti-inflammatory activity in the treatment of inflammatory skin conditions including acne, rosacea, and atopic dermatitis. Its anti-inflammatory mechanisms include inhibition of neutrophil chemotaxis and modulation of pro-inflammatory cytokine production.

Neuroprotection — Preclinical Evidence

Nicotinamide has demonstrated neuroprotective effects in preclinical models, including protection against ischemic brain injury and neurodegenerative conditions. These effects are mediated through NAD+-dependent mechanisms and modulation of oxidative stress.

Safety and Regulatory

Nicotinamide has a well-established safety profile when used appropriately. The tolerable upper intake level (UL) for nicotinamide is 5 mg/kg body weight, corresponding to approximately 350 mg/day for a 70 kg adult. Oral nicotinamide supplements have been studied at daily doses ranging from 25 mg to 6,000 mg for up to 5 years. High-dose nicotinamide (≥3 g/day) has been associated with hepatotoxicity in some studies and should only be used under medical supervision.

Regulatory Status:

• United States — Nicotinamide is regulated as a dietary supplement ingredient and food additive. It is Generally Recognized As Safe (GRAS) for use in food and dietary supplements. It is monographed in the USP with an assay specification of 99.0%–101.0% on dried basis.

• European Union — Nicotinamide is authorized as a food supplement ingredient and is permitted for use in food fortification in EU member states. It is monographed in the European Pharmacopoeia.

• Global Standards — Nicotinamide is monographed in the USP, European Pharmacopoeia, Chinese Pharmacopoeia (ChP), British Pharmacopoeia (BP), and Japanese Pharmacopoeia (JP). The International Pharmacopoeia specifies assay of 99.0%–101.0% of C₆H₅N₂O, calculated with reference to the dried substance.

Precautions: Nicotinamide is generally well tolerated at commonly used doses and does not cause flushing. High-dose nicotinamide (≥3 g/day) should only be used under medical supervision. Individuals with active liver disease should not use high-dose nicotinamide. Pregnant or lactating women and children should consult a healthcare professional before use. Nicotinamide may interact with certain medications, including anticoagulants and diabetes medications.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

89$/KG